Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Does Catheter ablation for Premature Ventricular Contractions remain unsuccessful in Arrhythmogenic Right Ventricular Cardiomyopathy?
  • +1
  • Erdi Babayiğit,
  • Andaç Karadeniz,
  • Kadir Uğur Mert,
  • Bulent Gorenek
Erdi Babayiğit
Kulu State Hospital

Corresponding Author:[email protected]

Author Profile
Andaç Karadeniz
Hınıs Public Hospital
Author Profile
Kadir Uğur Mert
Eskisehir Osmangazi University
Author Profile
Bulent Gorenek
Eskisehir Osmangazi University
Author Profile

Abstract

We have read with great interest the article “Efficacy of Catheter Ablation for Premature Ventricular Contractions (PVC) in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)” by Assis F.R. et. al. PVC ablation in ARVC was previously studied by Aras D. et al and they presented successful results.In this study, we believe that the study should not be considered as unsuccessful since 2 patients showed a decrease in PVC burden by more than 80% and in the other three patients between 45-70%. The demonstration of a decrease in PVC burden with catheter ablation in ARVD patients indicates that a second ablation may increase the success rate and decrease symptoms. The fact that ARVC has a complex substrate and the disease can progress is undoubtedly the most important factor in achieving the desired success with PVC ablation. Epicardial ablation with endocardial ablation has increased the chance of success in this patient group. In addition, given that BCSD ablation and basal heart rate are guaranteed by ICD implantation, we think that administration of the maximum dose of antiarrhythmic medication may create a significant improvement in these patients. And another factor, contact force sensing plays an important role in evaluating the effectiveness of the process. We suggest that with the current treatment modalities, a pharmacoablative combination therapy and re-ablation when necessary would be appropriate for such a complicated disease.
06 Apr 2021Submitted to Journal of Cardiovascular Electrophysiology
10 Apr 2021Submission Checks Completed
10 Apr 2021Assigned to Editor
11 Apr 2021Editorial Decision: Accept